Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Free Report)’s stock price was down 25.9% during mid-day trading on Thursday . The company traded as low as $0.30 and last traded at $0.30. Approximately 753,013 shares were traded during mid-day trading, an increase of 8% from the average daily volume of 697,326 shares. The stock had previously closed at $0.41.
Altamira Therapeutics Trading Down 25.9 %
The stock’s 50-day simple moving average is $0.40 and its two-hundred day simple moving average is $0.72.
Altamira Therapeutics Company Profile
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
Further Reading
- Five stocks we like better than Altamira Therapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What Are Dividend Champions? How to Invest in the Champions
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
